Martina Brueckmann

2003–2025 年に発表

116
論文数
27,007
被引用数
63
h 指数
111
i10 指数

被引用数

Martina Brueckmann の年別被引用数1999 年: 被引用 1 件2003 年: 被引用 4 件2004 年: 被引用 2 件2005 年: 被引用 11 件2006 年: 被引用 16 件2007 年: 被引用 22 件2008 年: 被引用 24 件2009 年: 被引用 24 件2010 年: 被引用 12 件2011 年: 被引用 35 件2012 年: 被引用 52 件2013 年: 被引用 61 件2014 年: 被引用 90 件2015 年: 被引用 87 件2016 年: 被引用 114 件2017 年: 被引用 108 件2018 年: 被引用 61 件2019 年: 被引用 254 件2020 年: 被引用 508 件2021 年: 被引用 1,163 件2022 年: 被引用 1,640 件2023 年: 被引用 1,388 件2024 年: 被引用 2,158 件2025 年: 被引用 1,132 件2026 年: 被引用 21 件2000〜2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,364 件、この内訳の 16.6%イギリス: 引用元論文 1,229 件、この内訳の 8.6%ドイツ: 引用元論文 933 件、この内訳の 6.6%イタリア: 引用元論文 818 件、この内訳の 5.7%カナダ: 引用元論文 812 件、この内訳の 5.7%中国: 引用元論文 656 件、この内訳の 4.6%オランダ: 引用元論文 598 件、この内訳の 4.2%フランス: 引用元論文 513 件、この内訳の 3.6%日本: 引用元論文 430 件、この内訳の 3%オーストラリア: 引用元論文 411 件、この内訳の 2.9%スウェーデン: 引用元論文 392 件、この内訳の 2.8%スペイン: 引用元論文 381 件、この内訳の 2.7%
0%16.6%その他 33%

分野

  • Medicine93.8%
  • Biochemistry, Genetics and Molecular Biology3.7%
  • Neuroscience0.5%
  • Engineering0.5%
  • Immunology and Microbiology0.4%
  • Health Professions0.2%
  • その他0.9%

トピック

  • Diabetes Treatment and Management13.3%
  • Heart Failure Treatment and Management9.1%
  • Cardiovascular Function and Risk Factors8%
  • Atrial Fibrillation Management and Outcomes6.4%
  • Pancreatic function and diabetes3.5%
  • Metabolism, Diabetes, and Cancer2.4%
  • その他57.3%

共著者

全論文

検索で開く
  1. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer - New England Journal of Medicine 2021 被引用: 4,618

  2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie‐France Seronde, Jindřich Špinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faı̈ez Zannad - New England Journal of Medicine 2020 被引用: 5,037

  3. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faı̈ez Zannad - The Lancet 2022 被引用: 974

  4. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 895

  5. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

    著者: , , , , , , , , , , - The Lancet 2020 被引用: 1,381

  6. Empagliflozin after Acute Myocardial Infarction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez - New England Journal of Medicine 2024 被引用: 262

  7. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , - Circulation 2020 被引用: 424

  8. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 811

  9. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

    著者: , , , , , , , , , , , , , - European Heart Journal 2022 被引用: 214

  10. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 1,496

  11. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

    著者: , , , , , , , , , , , , - Circulation 2020 被引用: 278

  12. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

    著者: , , , , , , , , , - European Heart Journal 2021 被引用: 253

  13. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

    著者: , , , , , , , , , , , , - Circulation 2022 被引用: 127

  14. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 被引用: 212

  15. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

    著者: , , , , , , , , , , , , , , , , , , , - Circulation 2020 被引用: 351

  16. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

    著者: , , , , , , , , , , , , , , , , , , , - Circulation 2021 被引用: 192

  17. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

    著者: , , , , , , , , , , , , , , , - Circulation 2022 被引用: 143

  18. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

    著者: , , , , , , , , , , - Journal of the American College of Cardiology 2021 被引用: 164

  19. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial

    著者: , , , , , , , , , , , - European Heart Journal 2022 被引用: 123

  20. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xavier Rosselló, Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Javed Butler - Circulation 2024 被引用: 89

  21. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , - JAMA Cardiology 2023 被引用: 60

  22. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

    著者: , , , , , , , , , - Circulation 2023 被引用: 75

  23. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

    著者: , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 被引用: 179

  24. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age

    著者: , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2022 被引用: 72